Hubei Jumpcan Pharmaceutical (600566) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was RMB 1.53 billion, down 36.51% year-over-year due to decreased sales of major products.

• Net profit attributable to shareholders fell 47.91% year-over-year to RMB 440 million, mainly from lower sales and higher cost ratios.

• Cash flow from operating activities decreased 40.70% year-over-year to RMB 794 million, reflecting reduced sales collections and other cash receipts.

Financial highlights

• Basic and diluted EPS were RMB 0.48, down 47.83% year-over-year.

• Total assets at quarter-end were RMB 18.33 billion, a slight decrease of 0.68% from year-end 2024.

• Shareholders’ equity increased 2.99% from year-end 2024 to RMB 15.14 billion.

• Non-recurring profit and loss items contributed RMB 48.2 million, mainly from government subsidies and financial asset gains.

Outlook and guidance

• Management attributes declines to reduced sales of key products and rising cost ratios, with no explicit forward guidance provided.